Pharma BD Deal Intelligence
A $600M bolt-on that quietly compounded into a ~$500M/year franchise still growing two decades later
Full analysis, sources & comparables →Bloomberg reports Genzyme agreed to acquire SangStat Medical, gaining transplant-rejection therapies, in a roughly $600 million cash transaction.
Reports Genzyme will buy SangStat for about $600 million in cash, acquiring products used to treat organ-transplant patients including lead drug Thymoglobulin.
Reports Genzyme completed its tender offer, with about 98% of SangStat shares tendered at $22.50 per share, closing the roughly $600 million acquisition.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Announced August 3-4, 2003 at $22.50/share all cash. Acquired Thymoglobulin (US SOT acute therapy leader). Closed September 2003. Sources: Bloomberg 8/3/2003, C&EN, SEC SC TO.
A $600M bolt-on that quietly compounded into a ~$500M/year franchise still growing two decades later
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Genzyme Corporation / SangStat Medical Corporation (this deal) | 2003 | $600M | 78 |
| Genzyme Corporation / ILEX Oncology Inc. | 2004 | $1.0B | 66 |
| Genzyme Corporation / Biomatrix Inc. | 2000 | $700M | 65 |
| Genzyme Corporation / Bone Care International, Inc. | 2005 | $600M | 61 |
| Genzyme Corporation / Novazyme Pharmaceuticals Inc. | 2001 | $138M | 54 |
| Genzyme Corporation / Verigen AG | 2005 | $50M | 29 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
← Browse all deals · How we score deals
More: 2003 deals · Genzyme Corporation deals